IL154057A0 - New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation - Google Patents

New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Info

Publication number
IL154057A0
IL154057A0 IL15405701A IL15405701A IL154057A0 IL 154057 A0 IL154057 A0 IL 154057A0 IL 15405701 A IL15405701 A IL 15405701A IL 15405701 A IL15405701 A IL 15405701A IL 154057 A0 IL154057 A0 IL 154057A0
Authority
IL
Israel
Prior art keywords
antagonist
pharmaceutical formulation
new combination
serotonin agonist
serotonin
Prior art date
Application number
IL15405701A
Other languages
English (en)
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of IL154057A0 publication Critical patent/IL154057A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL15405701A 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation IL154057A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (1)

Publication Number Publication Date
IL154057A0 true IL154057A0 (en) 2003-07-31

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15405701A IL154057A0 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Country Status (18)

Country Link
EP (1) EP1301476A1 (OSRAM)
JP (1) JP2004504376A (OSRAM)
KR (1) KR100845450B1 (OSRAM)
CN (1) CN1221254C (OSRAM)
AU (2) AU2001282734B2 (OSRAM)
BR (1) BR0112661A (OSRAM)
CA (1) CA2411192A1 (OSRAM)
EA (1) EA006604B1 (OSRAM)
HU (1) HUP0301346A3 (OSRAM)
IL (1) IL154057A0 (OSRAM)
MX (1) MXPA03000548A (OSRAM)
NO (1) NO20030304L (OSRAM)
NZ (1) NZ523216A (OSRAM)
PL (1) PL360309A1 (OSRAM)
SE (1) SE0002754D0 (OSRAM)
WO (1) WO2002008178A1 (OSRAM)
YU (1) YU2603A (OSRAM)
ZA (1) ZA200210234B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ATE495737T1 (de) * 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP5579262B2 (ja) 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
HUP0301346A3 (en) 2005-05-30
WO2002008178A1 (en) 2002-01-31
EA200300183A1 (ru) 2003-08-28
AU2001282734B2 (en) 2006-10-12
AU8273401A (en) 2002-02-05
KR20030036599A (ko) 2003-05-09
MXPA03000548A (es) 2004-04-05
CN1443162A (zh) 2003-09-17
HK1057536A1 (en) 2004-04-08
EA006604B1 (ru) 2006-02-24
BR0112661A (pt) 2003-06-24
SE0002754D0 (sv) 2000-07-21
NO20030304L (no) 2003-03-12
CA2411192A1 (en) 2002-01-31
KR100845450B1 (ko) 2008-07-10
NO20030304D0 (no) 2003-01-20
NZ523216A (en) 2005-05-27
YU2603A (sh) 2006-05-25
EP1301476A1 (en) 2003-04-16
PL360309A1 (en) 2004-09-06
JP2004504376A (ja) 2004-02-12
HUP0301346A2 (hu) 2003-08-28
CN1221254C (zh) 2005-10-05
ZA200210234B (en) 2004-03-18

Similar Documents

Publication Publication Date Title
AU8273401A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
HUP0303432A3 (en) Substituted pyridoindoles as serotonin agonists and antagonists and pharmaceutical compositions containing the compounds and their use
HUP0303530A3 (en) Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them
PT1255547E (pt) Composições de libertação controlada contendo agonistas e antagonistas opióides
HUP0103767A3 (en) Use of estrogen agonist/antagonist for preparation of pharmaceutical compositions available for treating osteoarthritis
AU6934600A (en) Cd40 ligand and cd40 agonist compositions and methods of use
HUP0102160A3 (en) Use of alpha-keto enamine derivatives as ingredients
IL154981A0 (en) Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
HUP0301146A3 (en) 2-chlor-5-nitrophenyl carboxamide derivatives, pharmaceutical compositions containing them and their use
HUP0203836A3 (en) 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use
EE200300284A (et) NMDA-retseptori agonisti farmatseutilised kompositsioonid
HUP0204458A3 (en) Derivatives of quinoline as alpha-2 antagonists and pharmaceutical compositions containing them
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
IL151369A (en) Use of tgf-beta antagonist for the preparation of pharmaceuticals
HUP0300419A3 (en) Estrogen agonist/antagonist metabolites, pharmaceutical compositions containing them and their use
IL144895A0 (en) Pharmaceutical compositions comprising benzaldehyde derivatives and several such new compounds
HUP0400386A3 (en) Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
HUP0105201A3 (en) The treatment of andropause using pharmaceutical compositions containing estrogen agonists/antagonists and testosterone
AU2002212888A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
HUP0303731A3 (en) Sulfonylguanidines and their use for preparation of pharmaceutical compositions
HUP0303880A2 (hu) Fenil-heterociklil-éter-származékok mint szerotonin-újrafelvétel-inhibitorok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
IL153487A0 (en) Pharmaceutical compositions and methods for use
IL153897A0 (en) Pharmaceutical compositions and methods for use